Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors

Irene Dalai, Edoardo Missiaglia, Stefano Barbi, Giovanni Butturini, Claudio Doglioni, Massimo Falconi, Aldo Scarpa

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Little is known about the molecular anomalies involved in the development and progression of malignancy of pancreatic endocrine tumors (PETs). A recently identified member of the Ras family, Ras homologue member I (ARHI ), has been shown to be involved in breast, ovary, and thyroid carcinogenesis. Unlike other members, it acts as a tumor suppressor gene that inhibits cell growth. Here we analyzed the mRNA expression of ARHI in 52 primary PETs and 16 normal pancreata using quantitative reverse transcription-polymerase chain reaction. ARHI expression showed a statistically significant difference between either normal pancreas or well-differentiated endocrine tumors (WDET) and poorly differentiated endocrine carcinomas (PDECs) (P <.001 and P <.001, respectively). Moreover, ARHI expression among WDEC samples was more heterogeneous than in WDET, with several tumors showing level of expression analogous to that observed in PDECs. A significant correlation between lower ARHI expression and shorter survival (P = .020) was identified, and a low ARHI expression was associated to a shorter time to progression (P <.001), even considering the proliferation index Ki67 in the multivariate analysis. ARHI is involved in PET progression. Its mRNA expression seemed to be a prognostic factor for disease outcome and, in association with the proliferative index Ki67, a predictor for a rapid tumor relapse.

Original languageEnglish
Pages (from-to)181-183
Number of pages3
JournalNeoplasia (United States)
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Disease-Free Survival
Neoplasms
Pancreas
Carcinoma
Messenger RNA
Tumor Suppressor Genes
Reverse Transcription
Ovary
Thyroid Gland
Carcinogenesis
Breast
Multivariate Analysis
Recurrence
Polymerase Chain Reaction
Growth

Keywords

  • ARHI
  • Pancreatic endocrine tumor
  • Survival
  • Time to progression
  • Tumor differentiation

ASJC Scopus subject areas

  • Cancer Research

Cite this

Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. / Dalai, Irene; Missiaglia, Edoardo; Barbi, Stefano; Butturini, Giovanni; Doglioni, Claudio; Falconi, Massimo; Scarpa, Aldo.

In: Neoplasia (United States), Vol. 9, No. 3, 03.2007, p. 181-183.

Research output: Contribution to journalArticle

Dalai, Irene ; Missiaglia, Edoardo ; Barbi, Stefano ; Butturini, Giovanni ; Doglioni, Claudio ; Falconi, Massimo ; Scarpa, Aldo. / Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. In: Neoplasia (United States). 2007 ; Vol. 9, No. 3. pp. 181-183.
@article{967d169470a94f6fbc715a371c91b0de,
title = "Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors",
abstract = "Little is known about the molecular anomalies involved in the development and progression of malignancy of pancreatic endocrine tumors (PETs). A recently identified member of the Ras family, Ras homologue member I (ARHI ), has been shown to be involved in breast, ovary, and thyroid carcinogenesis. Unlike other members, it acts as a tumor suppressor gene that inhibits cell growth. Here we analyzed the mRNA expression of ARHI in 52 primary PETs and 16 normal pancreata using quantitative reverse transcription-polymerase chain reaction. ARHI expression showed a statistically significant difference between either normal pancreas or well-differentiated endocrine tumors (WDET) and poorly differentiated endocrine carcinomas (PDECs) (P <.001 and P <.001, respectively). Moreover, ARHI expression among WDEC samples was more heterogeneous than in WDET, with several tumors showing level of expression analogous to that observed in PDECs. A significant correlation between lower ARHI expression and shorter survival (P = .020) was identified, and a low ARHI expression was associated to a shorter time to progression (P <.001), even considering the proliferation index Ki67 in the multivariate analysis. ARHI is involved in PET progression. Its mRNA expression seemed to be a prognostic factor for disease outcome and, in association with the proliferative index Ki67, a predictor for a rapid tumor relapse.",
keywords = "ARHI, Pancreatic endocrine tumor, Survival, Time to progression, Tumor differentiation",
author = "Irene Dalai and Edoardo Missiaglia and Stefano Barbi and Giovanni Butturini and Claudio Doglioni and Massimo Falconi and Aldo Scarpa",
year = "2007",
month = "3",
doi = "10.1593/neo.06838",
language = "English",
volume = "9",
pages = "181--183",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors

AU - Dalai, Irene

AU - Missiaglia, Edoardo

AU - Barbi, Stefano

AU - Butturini, Giovanni

AU - Doglioni, Claudio

AU - Falconi, Massimo

AU - Scarpa, Aldo

PY - 2007/3

Y1 - 2007/3

N2 - Little is known about the molecular anomalies involved in the development and progression of malignancy of pancreatic endocrine tumors (PETs). A recently identified member of the Ras family, Ras homologue member I (ARHI ), has been shown to be involved in breast, ovary, and thyroid carcinogenesis. Unlike other members, it acts as a tumor suppressor gene that inhibits cell growth. Here we analyzed the mRNA expression of ARHI in 52 primary PETs and 16 normal pancreata using quantitative reverse transcription-polymerase chain reaction. ARHI expression showed a statistically significant difference between either normal pancreas or well-differentiated endocrine tumors (WDET) and poorly differentiated endocrine carcinomas (PDECs) (P <.001 and P <.001, respectively). Moreover, ARHI expression among WDEC samples was more heterogeneous than in WDET, with several tumors showing level of expression analogous to that observed in PDECs. A significant correlation between lower ARHI expression and shorter survival (P = .020) was identified, and a low ARHI expression was associated to a shorter time to progression (P <.001), even considering the proliferation index Ki67 in the multivariate analysis. ARHI is involved in PET progression. Its mRNA expression seemed to be a prognostic factor for disease outcome and, in association with the proliferative index Ki67, a predictor for a rapid tumor relapse.

AB - Little is known about the molecular anomalies involved in the development and progression of malignancy of pancreatic endocrine tumors (PETs). A recently identified member of the Ras family, Ras homologue member I (ARHI ), has been shown to be involved in breast, ovary, and thyroid carcinogenesis. Unlike other members, it acts as a tumor suppressor gene that inhibits cell growth. Here we analyzed the mRNA expression of ARHI in 52 primary PETs and 16 normal pancreata using quantitative reverse transcription-polymerase chain reaction. ARHI expression showed a statistically significant difference between either normal pancreas or well-differentiated endocrine tumors (WDET) and poorly differentiated endocrine carcinomas (PDECs) (P <.001 and P <.001, respectively). Moreover, ARHI expression among WDEC samples was more heterogeneous than in WDET, with several tumors showing level of expression analogous to that observed in PDECs. A significant correlation between lower ARHI expression and shorter survival (P = .020) was identified, and a low ARHI expression was associated to a shorter time to progression (P <.001), even considering the proliferation index Ki67 in the multivariate analysis. ARHI is involved in PET progression. Its mRNA expression seemed to be a prognostic factor for disease outcome and, in association with the proliferative index Ki67, a predictor for a rapid tumor relapse.

KW - ARHI

KW - Pancreatic endocrine tumor

KW - Survival

KW - Time to progression

KW - Tumor differentiation

UR - http://www.scopus.com/inward/record.url?scp=33947357718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947357718&partnerID=8YFLogxK

U2 - 10.1593/neo.06838

DO - 10.1593/neo.06838

M3 - Article

VL - 9

SP - 181

EP - 183

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 3

ER -